Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy
Objective: Epilepsy is a common neurologic disorder affecting 1% of the world population with one-third of these patients failing to have seizure control for more than one year. Clobazam is a long-acting benzodiazepine used worldwide for the treatment of epilepsy. This antiepileptic drug has demon...
Autores Principales: | , |
---|---|
Otros Autores: | |
Formato: | Tesis de maestría (Master Thesis) |
Lenguaje: | Español (Spanish) |
Publicado: |
Universidad del Rosario
2016
|
Materias: | |
Acceso en línea: | http://repository.urosario.edu.co/handle/10336/11819 |
id |
ir-10336-11819 |
---|---|
recordtype |
dspace |
spelling |
ir-10336-118192021-03-01T19:22:52Z Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy Case-series Martínez-Micolta, Paula Lemus, Hernan Nicolás Mayor, Luis Carlos add-on treatment epilepsy antiepileptic drugs Clobazam Enfermedades Neurofisiología Epilepsia Enfermedades del sistema nervioso Neurología Objective: Epilepsy is a common neurologic disorder affecting 1% of the world population with one-third of these patients failing to have seizure control for more than one year. Clobazam is a long-acting benzodiazepine used worldwide for the treatment of epilepsy. This antiepileptic drug has demonstrated great clinical benefits with mild side effects. The objective of this study was to better understand the efficacy of clobazam treatment on adult patients with refractory epilepsy. Design: A retrospective review of 44 adult patients with diagnosis of epilepsy that were seen at our Epilepsy Clinic between January 2014 and May 2015. Setting: An outpatient epilepsy clinic at the Hospital Universitario Fundación Santa Fe de Bogota, Colombia. Participants: 44 adult patients with diagnosis of epilepsy. Measurements: Seizure frequency, adverse effects and the use of concomitant AEDs were reviewed in each of the patient´s clinical charts. Results: The responder rate of patients with clobazam was 52% at 3 months, 50% at 6 months and 55% at 12 month. Seizure freedom rates at 3, 6 and 12 months were 18%, 25% and 25% respectively. Clobazam related adverse events occurred only in four patients (9%) at the end of the twelve months with somnolence being the most common. Conclusion: These findings suggest that clobazam treatment in adult patients with focal or generalized epilepsy is effective and safe. Its use should be considered early when first-line agents fail to provide seizure control. Ninguno 2016-01-19 2016-03-07T21:44:23Z info:eu-repo/semantics/masterThesis info:eu-repo/semantics/acceptedVersion http://repository.urosario.edu.co/handle/10336/11819 spa info:eu-repo/semantics/openAccess application/pdf Universidad del Rosario Especialización en Neurofisiología Clínica Facultad de Medicina reponame:Repositorio Institucional EdocUR instname:Universidad del Rosario Gauthier AC, Mattson RH. Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy. CNS Neurosci Ther. 2015;21:543-8. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-1120. |
institution |
EdocUR - Universidad del Rosario |
collection |
DSpace |
language |
Español (Spanish) |
topic |
add-on treatment epilepsy antiepileptic drugs Clobazam Enfermedades Neurofisiología Epilepsia Enfermedades del sistema nervioso Neurología |
spellingShingle |
add-on treatment epilepsy antiepileptic drugs Clobazam Enfermedades Neurofisiología Epilepsia Enfermedades del sistema nervioso Neurología Martínez-Micolta, Paula Lemus, Hernan Nicolás Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy |
description |
Objective: Epilepsy is a common neurologic disorder affecting 1% of the world population with one-third of these patients failing to have seizure control for more than one year. Clobazam is a long-acting benzodiazepine used worldwide for the treatment of epilepsy. This antiepileptic drug has demonstrated great clinical benefits with mild side effects. The objective of this study was to better understand the efficacy of clobazam treatment on adult patients with refractory epilepsy.
Design: A retrospective review of 44 adult patients with diagnosis of epilepsy that were seen at our Epilepsy Clinic between January 2014 and May 2015.
Setting: An outpatient epilepsy clinic at the Hospital Universitario Fundación Santa Fe de Bogota, Colombia.
Participants: 44 adult patients with diagnosis of epilepsy.
Measurements: Seizure frequency, adverse effects and the use of concomitant AEDs were reviewed in each of the patient´s clinical charts.
Results: The responder rate of patients with clobazam was 52% at 3 months, 50% at 6 months and 55% at 12 month. Seizure freedom rates at 3, 6 and 12 months were 18%, 25% and 25% respectively. Clobazam related adverse events occurred only in four patients (9%) at the end of the twelve months with somnolence being the most common.
Conclusion: These findings suggest that clobazam treatment in adult patients with focal or generalized epilepsy is effective and safe. Its use should be considered early when first-line agents fail to provide seizure control. |
author2 |
Mayor, Luis Carlos |
author_facet |
Mayor, Luis Carlos Martínez-Micolta, Paula Lemus, Hernan Nicolás |
format |
Tesis de maestría (Master Thesis) |
author |
Martínez-Micolta, Paula Lemus, Hernan Nicolás |
author_sort |
Martínez-Micolta, Paula |
title |
Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy |
title_short |
Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy |
title_full |
Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy |
title_fullStr |
Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy |
title_full_unstemmed |
Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy |
title_sort |
clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy |
publisher |
Universidad del Rosario |
publishDate |
2016 |
url |
http://repository.urosario.edu.co/handle/10336/11819 |
_version_ |
1694382472855289856 |
score |
12,131701 |